Alison Kanski on Muck Rack

Alison Kanski

Verified
Seattle
As seen in: Precision Oncology News, Scientific American, The Weather Channel, DNews, Grist, Campaign (UK), PR Week, RenewEconomy, Campaign (US), Climate Central, GenomeWeb and
Biopharma reporter, Precision Oncology News @PrecOncNews Previously: @MMMnews @PRWeek. Views are mine, but I never tweet.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Alison

Contact Alison, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Tango Eyes Registrational Path for Combo With Revolution's Daraxonrasib After ASCO Stunner

|
By Alison Kanski 
| Precision Medicine Online
NEW YORK – Tango Therapeutics is advancing its PRMT5 inhibitor vopimetostat with Revolution Medicines' pan-RAS treatment daraxonasib into a registrational Phase III study testing the combination's first-line activity in MTAP-deleted pancreatic cancer.
Open in Who Shared Issue with article?

Cell Therapies Show Early Promise in Additional Solid Tumors at ASCO

|
By Alexandra Byrne, Alison Kanski 
| Precision Medicine Online
CHICAGO – Cell therapies are beginning to make inroads into new solid tumor types with early-stage trials presented at the American Society of Clinical Oncology's annual meeting showing promising efficacy for autologous tumor-infiltrating lymphocyte (TIL) therapies and CAR T-cell therapies beyond blood cancers.
Open in Who Shared Issue with article?

Early ctDNA Clearance Linked to Response, Survival on Lumakras, Vectibix in KRAS-Mutant Colorectal Cancer

|
By Alison Kanski 
| Precision Medicine Online
This article has been updated to add comments from Amgen about the exploratory analysis presented at ASCO. CHICAGO – Using circulating tumor DNA (ctDNA) testing proved to be an effective tool to monitor response and potentially guide treatment decisions in an exploratory analysis of a Phase III trial assessing Amgen's Lumakras (sotorasib) plus Vectibix (panitumumab) in KRAS G12C-mutant metastatic colorectal cancer.
Open in Who Shared Issue with article?
See all 423 licensed articles (1,017 Total)

Actions

Share this page

Get in touch with Alison

Contact Alison, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified